StockData
Krystal Biotech, Inc. logo

Krystal Biotech, Inc. (KRYS) stock

KRYSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 11/3052% above fair value
$315.34+16.79 (+5.62%)

Close on Nov 18, 2026Market cap $9.33BP/E 39.5Yield –

Krystal Biotech profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Krystal Biotech's profit margin for the twelve months ending Jun 30, 2026 was 54.8%. For fiscal 2025 it was 52.6%, against 30.7% the year before.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202552.6%+21.9
FY2024Dec 31, 202430.7%+9.1
FY2023Dec 31, 202321.6%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 202645.9%+6.0
Q1 FY2026Mar 31, 202648.1%+7.5
Q4 FY2025Dec 31, 202548.0%−1.9
Q3 FY2025Sep 30, 202581.2%+48.7
Q2 FY2025Jun 30, 202539.9%+17.8
Q1 FY2025Mar 31, 202540.5%+38.5
Q4 FY2024Dec 31, 202449.9%+29.3
Q3 FY2024Sep 30, 202432.4%−911.3
Q2 FY2024Jun 30, 202422.2%–
Q1 FY2024Mar 31, 20242.1%–
Q4 FY2023Dec 31, 202320.6%–
Q3 FY2023Sep 30, 2023943.7%–

More Krystal Biotech figures

See a number that looks wrong?